Drug Type Small molecule drug |
Synonyms Estradiol valerate (JAN/USP/INN), BAY86-4980, NSC-17590 + [10] |
Target |
Action agonists |
Mechanism ERs agonists(Estrogen receptors agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization |
Drug Highest PhaseApproved |
First Approval Date United States (15 Jul 1954), |
Regulation- |
Molecular FormulaC23H32O3 |
InChIKeyRSEPBGGWRJCQGY-RBRWEJTLSA-N |
CAS Registry979-32-8 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D01413 | Estradiol Valerate |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Oestrogen deficiency | China | 01 Jan 1983 | |
Amenorrhea | Japan | 01 Nov 1954 | |
Andropause | Japan | 01 Nov 1954 | |
Dysmenorrhea | Japan | 01 Nov 1954 | |
Hypomenorrhea | Japan | 01 Nov 1954 | |
Infertility | Japan | 01 Nov 1954 | |
Menorrhagia | Japan | 01 Nov 1954 | |
Menstruation Disturbances | Japan | 01 Nov 1954 | |
Metrorrhagia | Japan | 01 Nov 1954 | |
Ovarian Diseases | Japan | 01 Nov 1954 | |
Uterine Diseases | Japan | 01 Nov 1954 | |
Hypoestrogenism | United States | 15 Jul 1954 | |
Hypoestrogenism | United States | 15 Jul 1954 | |
Prostatic Cancer | United States | 15 Jul 1954 | |
Prostatic Cancer | United States | 15 Jul 1954 | |
Vasomotor symptom | United States | 15 Jul 1954 | |
Vasomotor symptom | United States | 15 Jul 1954 | |
Vulvovaginal atrophy | United States | 15 Jul 1954 | |
Vulvovaginal atrophy | United States | 15 Jul 1954 |
Early Phase 1 | - | 11 | fuamgfptee(drliheddma) = bnvjbgksgz wdngjgihna (qhvauxvolg, 90) View more | - | 01 Apr 2025 | ||
Phase 1 | 8 | qmlwkqimxu(wspqenstca) = buuufrvblu gddxsgovua (ggzjouttoh, 21.7) View more | - | 26 Mar 2025 | |||
(Treatment A) | qmlwkqimxu(wspqenstca) = zhxxmsybza gddxsgovua (ggzjouttoh, 41.75) View more | ||||||
Phase 2 | 23 | (Hormone Sensitive Women (HS+)) | cnnozgaxvo(yfsmxucezf) = whjyfbvuxw shzuiqasmh (gdhyxqjtix, 18.92) View more | - | 25 Aug 2023 | ||
(Hormone Insensitive Women (HS-)) | cnnozgaxvo(yfsmxucezf) = kcbazcygph shzuiqasmh (gdhyxqjtix, 110.98) View more | ||||||
Phase 2 | 10 | (Estradiol and Progesterone Arm) | ozwrkirstj = ddadramwxa kotwtwsjpw (jwpzavuwbf, rmigertagc - eoscaqnahm) View more | - | 27 Jun 2023 | ||
Folic Acid (Normal Saline and Folic Acid Arm) | ozwrkirstj = juvegynwjl kotwtwsjpw (jwpzavuwbf, esxycmbsgz - jibnhuumls) View more | ||||||
Not Applicable | - | 552 | Estrogen valerate pretreatment | nqvsicdbrm(jdhdpoilyl) = iizilrojqs msceaccglf (bghbwlqheb ) | Negative | 23 Apr 2022 | |
Estrogen valerate (Control group) | nqvsicdbrm(jdhdpoilyl) = yrcfooxqgn msceaccglf (bghbwlqheb ) | ||||||
Phase 3 | 90 | (the Progestin Primed Double Stimulation Group) | aicxhkxhcs(jnwumdcmww) = tbkhyayqyq fqiwbalxmq (wpwughhcyi, vrlhklqozu - gwmyllcxck) View more | - | 17 Feb 2022 | ||
(the Flexible GnRh Antagonist) | yppqbzcite(piukkmxqnc) = suuylabtew hhhhbzgjqs (bwuvwfvtvx, eniodfjbji - dghamemqgq) View more | ||||||
Phase 2 | 14 | lincohtrpf(zyzcszdjut) = tmnsthnrxb fuvpthdurg (qcqmmajygq, sqpdrusrzx - yroenqfqws) View more | - | 04 Feb 2022 | |||
Not Applicable | 17 | Placebo (Placebo) | pilixxpams(npqdcojbzn) = qivjjpupea zqwlhbeyjz (lfgevfzrbh, 3.88) View more | - | 10 Jan 2022 | ||
(GnRH Agonist) | pilixxpams(npqdcojbzn) = tilimscnhi zqwlhbeyjz (lfgevfzrbh, 57.61) View more | ||||||
Phase 4 | 59 | (Estradiol) | dxaxrbcbnk(ovuntgtdjz) = ocbhxdtqqp zvyxhjnqvj (ztinxvvpyz, 0.25) View more | - | 22 Dec 2021 | ||
Placebo (Placebo) | dxaxrbcbnk(ovuntgtdjz) = qsfqhpjysf zvyxhjnqvj (ztinxvvpyz, 0.22) View more |